KRYS
Price
$175.49
Change
+$3.66 (+2.13%)
Updated
Mar 4, 04:59 PM (EDT)
Capitalization
5.16B
69 days until earnings call
STRO
Price
$1.43
Change
-$0.00 (-0.00%)
Updated
Mar 4, 04:59 PM (EDT)
Capitalization
117.92M
22 days until earnings call
Ad is loading...

KRYS vs STRO

Header iconKRYS vs STRO Comparison
Open Charts KRYS vs STROBanner chart's image
Krystal Biotech
Price$175.49
Change+$3.66 (+2.13%)
Volume$1.95K
Capitalization5.16B
Sutro Biopharma
Price$1.43
Change-$0.00 (-0.00%)
Volume$19.04K
Capitalization117.92M
KRYS vs STRO Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. STRO commentary
Mar 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Buy and STRO is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 04, 2025
Stock price -- (KRYS: $172.07 vs. STRO: $1.43)
Brand notoriety: KRYS and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 127% vs. STRO: 157%
Market capitalization -- KRYS: $5.16B vs. STRO: $117.92M
KRYS [@Biotechnology] is valued at $5.16B. STRO’s [@Biotechnology] market capitalization is $117.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $398.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.48B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than STRO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 6 TA indicator(s) are bullish while STRO’s TA Score has 4 bullish TA indicator(s).

  • KRYS’s TA Score: 6 bullish, 4 bearish.
  • STRO’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than STRO.

Price Growth

KRYS (@Biotechnology) experienced а -7.93% price change this week, while STRO (@Biotechnology) price change was -16.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.35%. For the same industry, the average monthly price growth was -11.04%, and the average quarterly price growth was -7.19%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

STRO is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (-5.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.16B) has a higher market cap than STRO($118M). KRYS YTD gains are higher at: 9.837 vs. STRO (-22.283). KRYS has higher annual earnings (EBITDA): 181M vs. STRO (-69.95M). KRYS has more cash in the bank: 588M vs. STRO (388M). KRYS has less debt than STRO: KRYS (7.48M) vs STRO (24.9M). KRYS has higher revenues than STRO: KRYS (242M) vs STRO (161M).
KRYSSTROKRYS / STRO
Capitalization5.16B118M4,375%
EBITDA181M-69.95M-259%
Gain YTD9.837-22.283-44%
P/E Ratio57.36N/A-
Revenue242M161M150%
Total Cash588M388M152%
Total Debt7.48M24.9M30%
FUNDAMENTALS RATINGS
KRYS vs STRO: Fundamental Ratings
KRYS
STRO
OUTLOOK RATING
1..100
7765
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
18100
SMR RATING
1..100
7696
PRICE GROWTH RATING
1..100
4993
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STRO's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for KRYS (79). This means that STRO’s stock grew somewhat faster than KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is significantly better than the same rating for STRO (100). This means that KRYS’s stock grew significantly faster than STRO’s over the last 12 months.

KRYS's SMR Rating (76) in the Pharmaceuticals Major industry is in the same range as STRO (96). This means that KRYS’s stock grew similarly to STRO’s over the last 12 months.

KRYS's Price Growth Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for STRO (93). This means that KRYS’s stock grew somewhat faster than STRO’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as STRO (100). This means that KRYS’s stock grew similarly to STRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSSTRO
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 15 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UVIX36.895.39
+17.11%
2x Long VIX Futures ETF
EUFN27.920.48
+1.75%
iShares MSCI Europe Financials ETF
UGE20.100.22
+1.08%
ProShares Ultra Consumer Staples
FLMX24.53-0.28
-1.12%
Franklin FTSE Mexico ETF
IYM135.37-2.97
-2.15%
iShares US Basic Materials ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with PRME. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-4.01%
PRME - KRYS
46%
Loosely correlated
-11.31%
PRTA - KRYS
46%
Loosely correlated
-9.36%
ZLDPF - KRYS
45%
Loosely correlated
-14.19%
RGNX - KRYS
45%
Loosely correlated
-9.89%
ALT - KRYS
44%
Loosely correlated
-10.08%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with NUVB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then NUVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
-10.06%
NUVB - STRO
52%
Loosely correlated
-7.61%
STOK - STRO
51%
Loosely correlated
-5.73%
TRDA - STRO
47%
Loosely correlated
-5.11%
KRYS - STRO
45%
Loosely correlated
-4.01%
ALGS - STRO
44%
Loosely correlated
-14.23%
More